Skip to content
Home
Visit our other Journals
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Specialties
Hematology
Oncology
Musculoskeletal Disorder
Rare Disease
Metabolic Disorder
Cardiovascular Disease
Ophthalmology
Neurology
Infectious Disease
View all Specialties
Technologies
Cell Therapy
MSC
iPSC
Gene Therapy
Genome Editing
Extracellular Vesicles
CAR-T Therapy
TCR Therapy
Tissue-Engineering & Biomaterials
View all Technologies
Topics
Treatment
Immuno-Oncology
Trial Updates
Perspectives
Manufacturing
COVID-19
View all Topics
Conferences
ASH 2022
TCT 2022
Meeting on the Med 2022
ICLE 2022
Advanced Therapies Week 2022
TERMIS 2021
ESGCT 2021
Meeting on the Mesa 2021
Advanced Therapies 2021
View all Conferences
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
University of Pennsylvania
3:58
Results from the first-in-human trial of huCART19-IL18 in patients with R/R NHL and CLL
Jakub Svoboda
• 11 Dec 2022
1:27
Updates in cell and gene therapy approvals
Bruce Levine
• 27 Jan 2022
1:44
The role of automation in manufacturing CAR T-cells
Bruce Levine
• 27 Jan 2022
1:12
Trends and innovations within the advanced therapy sector
Bruce Levine
• 27 Jan 2022
4:09
Treating volumetric muscle loss with tissue-engineered products
Suradip Das
• 19 Nov 2021
3:29
Accelerating regenerative therapies for volumetric muscle loss
Suradip Das
• 19 Nov 2021
2:44
Challenges with translating gene therapies for neurodevelopmental disorders
Ralf Schmid
• 16 Nov 2021
2:56
Non-viral gene delivery & gene editing: highlights from ESGCT
Ralf Schmid
• 16 Nov 2021
3:49
The gene-replacement therapy landscape for CDKL5-deficiency disorder
Ralf Schmid
• 16 Nov 2021
4:23
AAV9-mediated gene therapy for CDKL5-deficiency disorder
Ralf Schmid
• 16 Nov 2021
2:11
Addressing CAR-T manufacturing challenges
Bruce Levine
• 28 May 2021
4:27
Impact of COVID-19 on CAR T-cell therapies
David L. Porter
• 17 Sep 2020
4:51
Anti-CD19 CAR T-cells for adults
David L. Porter
• 9 Sep 2020
5:25
Long-term outcomes of anti-CD19 CAR-T in R/R CLL
David L. Porter
• 16 Sep 2020
